Journal Mobile Options
Table of Contents
Vol. 7, No. 1-3, 2010
Issue release date: April 2010
Neurodegenerative Dis 2010;7:76–79
(DOI:10.1159/000285510)

Misframed Proteins and Neurodegeneration: A Novel View on Alzheimer’s and Parkinson’s Diseases

Dennissen F.J.A. · Kholod N. · Steinbusch H.W.M. · Van Leeuwen F.W.
DepartmentofNeuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Sporadic forms of Alzheimer’s and Parkinson’s diseases are the most frequent forms of their kind. Together with Huntington’s disease, they belong to the so called ‘conformational diseases’ as they share a common feature in the accumulation of insoluble protein deposits. In this review, we focus on the significance of the ubiquitin-proteasome system in conformational diseases and the possible consequences due to the accumulation of aberrant proteins. In all forms of Alzheimer’s and Huntington’s diseases, but not in Parkinson’s disease, we have shown the presence of misframed proteins such as misframed ubiquitin (UBB+1) of which we have determined the functional relevance in vitro and in vivo.Misframed proteins are the result of the inaccurate transcription of monotonic sequences in the genome and their subsequent translation. This process has been called ‘molecular misreading’. In the present review, we will discuss the present state of the art with regard to UBB+1 and amyloid precursor protein APP+1.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA: Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216–223.
  2. Schnabel J: Alzheimer’s theory makes a splash. Nature 2009;459:310.
  3. Nikolaev A, McLaughlin T, O’Leary DD, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457:981–989.
  4. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM: Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients. Science 1998;279:242–247.
  5. Gerez L, de Haan A, Hol EM, Fischer DF, van Leeuwen FW, van Steeg H, Benne R: Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for beta-amyloid precursor protein and ubiquitin B. Neurobiol Aging 2005;26:145–155.
  6. Fischer DF, De Vos RA, Van Dijk R, De Vrij FM, Proper EA, Sonnemans MA, Verhage MC, Sluijs JA, Hobo B, Zouambia M, Steur EN, Kamphorst W, Hol EM, Van Leeuwen FW: Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 2003;17:2014–2024.
  7. Schwartz AL, Ciechanover A: Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009;49:73–96.
  8. Tan Z, Sun X, Hou FS, Oh HW, Hilgenberg LG, Hol EM, van Leeuwen FW, Smith MA, O’Dowd DK, Schreiber SS: Mutant ubiquitin found in Alzheimer’s disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ 2007;14:1721–1732.
  9. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, Hol EM: Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J Cell Sci 2007;120:1615–1623.
  10. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP: Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002;157:417–427.
  11. Park Y, Yoon SK, Yoon JB: The HECT domain of TRIP12 ubiquitinates substrates of the ubiquitin fusion degradation pathway. J Biol Chem 2009;284:1540–1549.
  12. Verhoef LG, Heinen C, Selivanova A, Halff EF, Salomons FA, Dantuma NP: Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates. FASEB J 2009;23:123–133.
  13. Paine S, Bedford L, Thorpe JR, Mayer RJ, Cavey JR, Bajaj N, Sheppard PW, Lowe J, Layfield R: Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration. Neurosci Lett 2009;460:205–208.
  14. Shabek N, Herman-Bachinsky Y, Ciechanover A: Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation. Proc Natl Acad Sci USA 2009;106:11907–11912.
  15. Kim HT, Kim KP, Uchiki T, Gygi SP, Goldberg AL: S5a promotes protein degradation by blocking synthesis of nondegradable forked ubiquitin chains. EMBO J 2009;28:1867–1877.
  16. de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, Hol EM, Roos RA, van Leeuwen FW: Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 2004;13:1803–1813.
  17. van Leeuwen FW, van Tijn P, Sonnemans MA, Hobo B, Mann DM, Van Broeckhoven C, Kumar-Singh S, Cras P, Leuba G, Savioz A, Maat-Schieman ML, Yamaguchi H, Kros JM, Kamphorst W, Hol EM, de Vos RA, Fischer DF: Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology 2006;66:S86–S92.
  18. Fischer DF, van Dijk R, van Tijn P, Hobo B, Verhage MC, van der Schors RC, Li KW, van Minnen J, Hol EM, van Leeuwen FW: Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol Aging 2009;30:847–863.
  19. Pawlik M, Otero DA, Park M, Fischer WH, Levy E, Saitoh T: Proteins that bind to the RERMS region of beta amyloid precursor protein. Biochem Biophys Res Commun 2007;355:907–912.
  20. Hol EM, van Dijk R, Gerez L, Sluijs JA, Hobo B, Tonk MT, de Haan A, Kamphorst W, Fischer DF, Benne R, van Leeuwen FW: Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. J Biol Chem 2003;278:39637–39643.
  21. van Dijk R, Fischer DF, Sluijs JA, Sonnemans MA, Hobo B, Mercken L, Mann DM, Hol EM, van Leeuwen FW: Frame-shifted amyloid precursor protein found in Alzheimer’s disease and Down’s syndrome increases levels of secreted amyloid beta40. J Neurochem 2004;90:712–723.
  22. Fischer DF, Hol EM, Hobo B, van Leeuwen FW: Alzheimer-associated APP+1 transgenic mice: frameshift beta-amyloid precursor protein is secreted in cerebrospinal fluid without inducing neuropathology. Neurobiol Aging 2006;27:1445–1450.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00